Standout Papers

Effects of Intensive Glucose Lowering in Type 2 Diabetes 2008 2026 2014 2020 5.4k
  1. Effects of Intensive Glucose Lowering in Type 2 Diabetes (2008)
    Hertzel C. Gerstein, Michael E. Miller et al. New England Journal of Medicine
  2. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (2016)
    Steven P. Marso, Gilbert H. Daniels et al. New England Journal of Medicine
  3. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2012)
    Richard M. Bergenstal, John B. Buse et al. Diabetologia
  4. Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy (2008)
    David M. Nathan, John B. Buse et al. Diabetes Care
  5. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2018)
    Melanie J. Davies, David A. D’Alessio et al. Diabetes Care
  6. Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach (2012)
    Silvio E. Inzucchi, Richard M. Bergenstal et al. Diabetes Care
  7. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes (2014)
    Silvio E. Inzucchi, Richard M. Bergenstal et al. Diabetes Care
  8. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes (2015)
    Jennifer B. Green, M. Angelyn Bethel et al. New England Journal of Medicine
  9. The Metabolic Syndrome: Time for a Critical Appraisal (2005)
    Richard Kahn, John B. Buse et al. Diabetes Care
  10. Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes (2017)
    Rury R. Holman, M. Angelyn Bethel et al. New England Journal of Medicine
  11. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6) (2009)
    John B. Buse, Julio Rosenstock et al. The Lancet
  12. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2018)
    Melanie J. Davies, David A. D’Alessio et al. Diabetologia
  13. Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Sulfonylurea-Treated Patients With Type 2 Diabetes (2004)
    John B. Buse, Robert R. Henry et al. Diabetes Care
  14. Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy (2006)
    David M. Nathan, John B. Buse et al. Diabetes Care
  15. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study (2008)
    Daniel J. Drucker, John B. Buse et al. The Lancet
  16. Liraglutide and Renal Outcomes in Type 2 Diabetes (2017)
    Johannes F.E. Mann, David D. Ørsted et al. New England Journal of Medicine
  17. Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2022)
    Melanie J. Davies, Vanita R. Aroda et al. Diabetes Care
  18. 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2019)
    John B. Buse, Deborah J. Wexler et al. Diabetes Care
  19. Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus (2006)
    John B. Buse, Henry N. Ginsberg et al. Diabetes Care
  20. How Do We Define Cure of Diabetes? (2009)
    John B. Buse, Sonia Caprio et al. Diabetes Care
  21. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study (2010)
    M. E Miller, RM Bergenstal et al. BMJ
  22. Molecular Biology of Mammalian Glucose Transporters (1990)
    Graeme I. Bell, Toshiaki Kayano et al. Diabetes Care
  23. Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD) (2009)
    Bernard Zinman, John Gerich et al. Diabetes Care
  24. Microneedle-array patches loaded with hypoxia-sensitive vesicles provide fast glucose-responsive insulin delivery (2015)
    Jicheng Yu, Yuqi Zhang et al. Proceedings of the National Academy of Sciences
  25. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364–1379 (2013)
    SE Inzucchi, RM Bergenstal et al. Diabetes Care
  26. Effectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes (2010)
    Richard M. Bergenstal, William V. Tamborlane et al. New England Journal of Medicine
  27. Intensive Glycemic Control and the Prevention of Cardiovascular Events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials (2008)
    Jay S. Skyler, Richard M. Bergenstal et al. Diabetes Care
  28. A Comparison of Lipid and Glycemic Effects of Pioglitazone and Rosiglitazone in Patients With Type 2 Diabetes and Dyslipidemia (2005)
    Ronald Goldberg, David M. Kendall et al. Diabetes Care
  29. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years (2007)
    David C. Klonoff, John B. Buse et al. Current Medical Research and Opinion
  30. Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium–Glucose Cotransporter 2 Inhibition (2015)
    Anne L. Peters, Elizabeth Buschur et al. Diabetes Care
  31. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy (2008)
    David M. Nathan, John B. Buse et al. Diabetologia
  32. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes (2015)
    Silvio E. Inzucchi, Richard M. Bergenstal et al. Diabetologia
  33. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2022)
    Melanie J. Davies, Vanita R. Aroda et al. Diabetologia
  34. Glucose-responsive insulin patch for the regulation of blood glucose in mice and minipigs (2020)
    Jicheng Yu, Jinqiang Wang et al. Nature Biomedical Engineering
  35. Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study (2012)
    John B. Buse, Michael A. Nauck et al. The Lancet
  36. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis (2017)
    M. Angelyn Bethel, Rishi Patel et al. The Lancet Diabetes & Endocrinology
  37. Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes (2017)
    Steven P. Marso, Darren K. McGuire et al. New England Journal of Medicine
  38. 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2019)
    John B. Buse, Deborah J. Wexler et al. Diabetologia
  39. Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes (2017)
    Satish K. Garg, Robert R. Henry et al. New England Journal of Medicine
  40. Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From aDiabetes CareEditors’ Expert Forum (2017)
    William T. Cefalu, Sanjay Kaul et al. Diabetes Care
  41. COVID-19, Hyperglycemia, and New-Onset Diabetes (2021)
    Kamlesh Khunti, Stefano Del Prato et al. Diabetes Care
  42. Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER (2021)
    Ahmed M. Shaman, Stephen C. Bain et al. Circulation
  43. Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS‐CVOT design and baseline characteristics (2023)
    Stephen J. Nicholls, Deepak L. Bhatt et al. American Heart Journal
  44. Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes (2025)
    Darren K. McGuire, Nikolaus Marx et al. New England Journal of Medicine

Immediate Impact

1 by Nobel laureates 10 from Science/Nature 134 standout
Sub-graph 1 of 16

Citing Papers

Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes
2024 Standout
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
2023 Standout
69 intermediate papers

Works of John B. Buse being referenced

Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
2017 Standout
Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors
2016
and 51 more

Author Peers

Author Last Decade Papers Cites
John B. Buse 54476 25946 19976 595 76.1k
Bernard Zinman 43046 18193 17578 643 61.2k
Ele Ferrannini 28308 14917 13056 523 50.0k
David R. Matthews 42881 17935 16026 266 73.6k
Markku Laakso 22794 15999 11434 667 56.6k
Melanie J. Davies 30305 10447 9575 994 54.5k
Steven E. Kahn 20367 12423 12627 467 45.2k
Steven M. Haffner 32314 10990 10874 517 60.5k
Daniel J. Rader 17011 13069 25601 761 56.9k
Gerald M. Reaven 29768 13376 10168 663 58.0k
Rury R. Holman 28999 10634 9037 347 39.3k

All Works

Loading papers...

Rankless by CCL
2026